Global Health Q1 FY27: Profit down 10%, revenue up 22%

Key takeaway from the quarter

Global Health Limited (Medanta) reported a weaker profit print for the quarter ended June 30, 2026 (Q1FY27) even as revenue rose strongly year-on-year. The company’s standalone net profit fell 10% YoY, while revenue from operations increased 22% YoY. Alongside the quarterly update, the company also communicated key dividend timelines for FY26 under the Listing Regulations.

Q1FY27 results: standalone performance

For Q1FY27, Global Health posted a standalone net profit of ₹137.31 crore, down from ₹151.96 crore in the same quarter last year (Q1FY26). Despite the decline in profit, revenue from operations grew to ₹1,078.72 crore, marking 22% YoY growth.

The numbers indicate a quarter where topline momentum remained intact, but profitability did not keep pace with revenue growth. The disclosure provided the quarter-end date as June 30, 2026.

Consolidated profit numbers for Q1FY27

On a consolidated basis, profit after tax (PAT) stood at ₹157.25 crore in Q1FY27. This was marginally lower than ₹158.98 crore in Q1FY26. The gap between standalone and consolidated profit was modest in the reported period.

Dividend: record date and AGM schedule

Pursuant to Regulation 42 of the Listing Regulations, Global Health fixed August 14, 2026 as the record date to determine shareholder eligibility for the final dividend for FY26. The proposed final dividend is ₹0.50 per equity share.

The dividend is subject to shareholder approval at the company’s 22nd Annual General Meeting (AGM), scheduled for September 16, 2026.

Trading window closure ahead of results review

Global Health also disclosed that it closed its trading window on July 1, 2026 for all designated persons. This was communicated in the context of the company heading into its Q1 FY27 results review.

The source text noted that the exact date of the Q1 results review was not independently verified, but the trading window closure date was specified.

FY26 context: full-year income and profit growth

For the full year ended March 31, 2026 (FY26), Global Health reported consolidated total income of ₹4,508.90 crore, up 19.6% YoY. Consolidated PAT for FY26 was ₹554.10 crore, representing 15.1% YoY growth.

The board recommendation for the FY26 final dividend was reiterated as ₹0.50 per equity share (face value ₹2 each), described as 25% of face value.

Recent quarterly reference points from FY26

The company’s Q4FY26 consolidated total income was reported at ₹1,195.79 crore, up from ₹1,142.83 crore in Q3FY26 and ₹954.18 crore in Q4FY25. For Q4FY26, standalone total income was reported at ₹996.43 crore.

For Q4FY26, standalone PAT was ₹124.13 crore, compared with ₹79.91 crore in Q3FY26 and ₹93.41 crore in Q4FY25.

Stock snapshot and listed prices mentioned

As per the provided market snapshot dated June 24, 2026, Global Health’s share price was ₹1,322.6. The stock opened at ₹1,303 and the previous close was ₹1,302.8. The same snapshot also listed the price as ₹1,322.6 on NSE and ₹1,319.4 on BSE as of June 24, 2026.

The text also mentioned a 1-year dividend yield of 0.04%.

Summary table of reported data

Company identifiers and contact details cited

The article text referenced “Medanta - Mediclinic” and listed contact details including 011-44114411 and compliance@medanta.org. It also included the identifier 543654.

Why the Q1FY27 print matters

The Q1FY27 update brings together three investor-relevant signals based on the reported facts: a sharp revenue rise in the standalone business, a year-on-year decline in standalone profit, and a nearly flat consolidated PAT versus the prior-year quarter. Separately, the company has set clear dates around the FY26 final dividend process, with the record date and AGM schedule specified.

Conclusion

Global Health’s Q1FY27 showed 22% YoY growth in standalone revenue but a 10% YoY decline in standalone net profit, with consolidated PAT also slightly lower than last year. The next key dates for investors are August 14, 2026 (record date) and September 16, 2026 (AGM) for the FY26 final dividend proposal.